Introduction
Parkinson's disease is a chronic and progressive neurodegenerative disorder characterized by asymmetrical limb bradykinesia, rigidity and tremor. Non-motor symptoms such as chronic fatigue, depression, dementia and sleep disturbances are also frequent and can greatly impact on quality of life. Disabling fatigue is estimated to occur in about one-third of patients with Parkinson's disease (Karlsen et al., 1999; Abe et al., 2000; Friedman and Friedman, 2001; Lou et al., 2001; Herlofson and Larsen, 2002) . Sometimes this symptom antedates the development of motor disturbances. Hagell and Brundin (2009) have recently reported that in a cohort of 118 consecutive patients with Parkinson's disease, 18 (32%) had fatigue before any motor disturbance. The PRIAMO study (Barone et al., 2009) reported that fatigue occurred in 58.1% of a cohort of 1072 patients, ranging from 37.7% in patients with Hoehn and Yahr stage 1-81.6% in stages 4-5. Affected patients typically complain of a feeling of constant exhaustion or tiredness, either mental, physical or both (Brown et al., 2005) . However, severity of mental fatigue does not correlate well with physical fatigue, suggesting that the two conditions are caused by independent mechanisms in Parkinson's disease (Lou et al., 2001) .
The reason for the high prevalence of fatigue in Parkinson's disease remains poorly understood. In most studies, the presence and severity of fatigue does not correlate with disease duration or degree of motor disability. Additionally, no direct relationship between presence of fatigue and type, dosage and duration of anti-parkinsonian medication has been found (Abe et al., 2000; Friedman and Friedman, 2001; Hagell and Brundin, 2009) . Conversely, the presence of depression, nocturnal sleep disturbance and autonomic impairment are all thought to exacerbate the subjective experience of fatigue (Karlsen et al., 1999; Lou et al., 2001; Alves et al., 2004; Hagell and Brundin, 2009 ). However, these factors cannot completely explain the high prevalence of fatigue in Parkinson's disease, as the symptom is common in non-depressed patients and is also experienced by patients with no complaint of sleep disorders (Friedman and Friedman, 1993; Karlsen et al., 1999; Lou et al., 2001) .
It has recently been proposed that basal ganglia dysfunction plays a role in the mechanism of fatigue in diseases of the central nervous system (Chaudhuri et al., 2000 (Chaudhuri et al., , 2003 (Chaudhuri et al., , 2004 . Several observations would support this view. In patients with multiple sclerosis, fatigue has been reported to be associated with reduced glucose metabolism in the frontal cortex and the basal ganglia (Roelcke et al., 1997) . Bilateral posteroventral pallidotomy for treatment of Parkinson's disease can also lead to profound fatigue, sleepiness, changes in behaviour and poor initiative in executive functions despite improvement in motor control (Ghika et al., 1999) . However, a recent study among levodopa-naïve patients with Parkinson's disease found that patients with fatigue had similar striatal dopamine transporter uptake compared with patients without fatigue (Schifitto et al., 2008) . These findings indicate that non-dopaminergic basal ganglia pathways are most likely to be involved in fatigue generation in Parkinson's disease or, if dopaminergic dysfunction plays a role, it involves extrastriatal projections.
Several studies have suggested that serotonergic deficiency is a pathophysiological factor in chronic fatigue syndrome without parkinsonism (Narita et al., 2003; Yamamoto et al., 2004; Cleare et al., 2005; Katafuchi et al., 2005) . Accordingly, reduced serotonin transmission could have a role in the occurrence of fatigue in patients with Parkinson's disease. In this study, we used 18 F-dopa and 11 C-N,N-dimethyl-2-(2-amino-4-cyanophenylthio) (Hamilton, 1960) 416 and Beck Depression Inventory (Beck et al., 1961) 49] and sleep disturbances, specifically excessive daytime sleepiness [Epworth Sleepiness Scale (Johns, 1991 ) 48] were not enrolled. The patients were divided into two groups according to the presence (n = 10) or absence (n = 10) of fatigue. A presence of fatigue was defined as a score 58 on the Parkinson Fatigue Scale (Brown et al., 2005) . The Parkinson Fatigue Scale has specifically been designed to measure fatigue in a Parkinson's disease population, taking into account possible overlapping with other motor and non-motor symptoms of Parkinson's disease. In particular, it provides a measure of fatigue, which is independent of affective, sleep and cognitive disturbances. The scale contains 16 questions. Seven of them are related to the presence or absence of subjective experience of fatigue, whereas the remaining nine measure the impact of fatigue on daily activity. Each item has five response options from '1' (strongly disagree) to '5' (strongly agree). In this article we scored each item using a binary scoring method. In this method, the response 'agree' and 'strongly agree' are scored '1', and all other responses are scored '0'. The total score ranges from 0 to 16, 16 being the worst score and 8 the cut-off score to identify patients who perceive fatigue to be a problem (Brown et al., 2005) .
The two groups of patients with Parkinson's disease with and without fatigue were matched for age, disease duration, daily intake of levodopa equivalent units and Unified Parkinson's Disease Rating Scale (UPDRS) (Fahn and Elton, 1987) scores in both OFF and ON conditions. Table 1 summarizes the demographics of all patients investigated. All patients had a stable response to their dopamine replacement therapy and none were taking medication targeting serotonergic and noradrenergic systems. Levodopa equivalent units were calculated as follows: 100 mg levodopa = 2 mg cabergoline = 1 mg pramipexole or 1 mg pergolide = 5 mg ropinirole = 4 mg rotigotine patch = 0.5 mg rasagiline. The conversion factors below were used for controlled release levodopa and levodopa/carbidopa/entecapone combination: 125 mg controlled release levodopa = 65 mg levodopa; 50 mg levodopa/carbidopa/entecapone combination = 65 mg levodopa.
Eight patients with Parkinson's disease with fatigue and seven patients with Parkinson's disease without fatigue had both 18 F-dopa and 11 C-DASB PET. The remaining five patients had only one scan as they withdrew their consent after the first PET session. In summary, 10 patients from the Parkinson's disease with fatigue group and nine from the Parkinson's disease without fatigue group had 18 F-dopa PET and eight patients from the Parkinson's disease with fatigue group and eight from the Parkinson's disease without fatigue group had 11 C-DASB PET ( Since the main aim of this project was to compare function between patients with Parkinson's disease with and without fatigue, no healthy control subjects were scanned during this study. However, 11 C-DASB PET findings for our two Parkinson's disease groups were compared with those of nine healthy volunteers (all males, age 44.6 AE 5.5 years) from the Unit's database. None of these healthy volunteers had any significant medical history including current or previous medical history of neurological or psychiatric disorders.
PET protocol
PET scanning took place at the Cyclotron Building, Hammersmith Hospital, Hammersmith Imanet, GE Healthcare, London, UK, and all PET scans were performed using an ECAT EXACT HR+ (CTI/Siemens 962) camera, which covers an axial field of view of 15.5 cm and provides 63 transaxial planes. The tomograph has an axial resolution of 5.4 mm full width at half maximum and a transaxial resolution of 5.6 mm full width at half maximum at 10 cm distance from the centre (Brix et al., 1997) . All patients had their levodopa medication stopped for at least 12 h before PET, and dopamine agonists had been stopped 3 days before scanning.
The scanning protocol for 18 F-dopa involved 3D acquisition over 
PET analysis
Parametric images of specific 18 F-dopa uptake (Ki maps) were created on a voxel-wise basis using a standard multiple-time graphical approach (Patlak et al., 1983) over 30-90 min with an occipital reference input function (Rakshi et al., 1999) . Integrated images (ADD images) of the dynamic time series of 18 F-dopa uptake collected over 30-90 min after intravenous tracer administration were also created for spatial normalization purposes (Rakshi et al., 1999) . Spatial normalization of ADD images and Ki maps into standard Montreal Neurological Institute (MNI) stereotaxic space was performed using statistical parametric mapping (SPM) software package (www.fil.ion.ucl.ac.uk/spm) implemented in MATLAB5. First the ADD images were normalized to a smoothed 18 F-dopa template in MNI space created in-house from healthy control subjects. Then the transformation parameters were applied to the respective 18 F-dopa Ki maps.
Parametric images of specific 11 C-DASB binding potentials [BP ND (non-displaceable) in consensus nomenclature (Innis et al., 2007) ] were generated on a voxel-wise basis for the whole brain using a basis function implementation of the simplified reference region compartmental model with the cerebellum providing the reference tissue input function (Gunn et al., 1997) . Integrated ADD images of 11 C-DASB uptake were also created for spatial normalization purposes. a In this patient the spatial normalization of the individual parametric image to the 11 C-DASB template was unsuccessful and the patient was excluded from the analysis. ADD images and parametric images of 11 C-DASB BP ND were then normalized, using SPM software, to a smoothed 11 C-DASB ADD image template in MNI space created in-house from healthy control subjects.
Extraction of region of interest data
To extract region of interest data we used a standard object map in MNI space. The standard object map contained regions defined for caudate nucleus, putamen, ventral striatum, thalamus and median raphe. These regions of interest had been freehand-traced using ANALYZE 8. C-DASB BP ND were spatially smoothed using a 6 Â 6 Â 6 mm (full width at half maximum) isotropic Gaussian kernel.
For each tracer, between-group comparisons were performed by using weighted contrasts to localize significant decreases in mean voxel tracer uptake in the Parkinson's disease with fatigue group compared with the Parkinson's disease without fatigue group. The contrast was used to generate maps of Z-scores on a voxel basis using the general linear model (Friston et al., 1995) . The statistical maps were visualized at a threshold P50.01 (Z-score = 2.33) and any resulting cluster with a P50.05 is reported.
Statistical analysis
Statistical analyses of clinical data were performed with Statistical Package for the Social Sciences (SSPS 16 for Windows, SPSS Inc., Chicago, IL, USA). Comparisons between groups were made using a non-parametric unpaired test (Mann-Whitney U-test) or non-parametric ANOVA (Kruskal-Wallis test) as appropriate. Post hoc comparisons after Kruskal-Wallis test were performed using two-tailed Mann-Whitney U-test. Resulting P-values were corrected according to the Bonferroni method.
Correlations between variables were tested with Spearman rank correlation.
Results
Severity of fatigue in the whole group of 20 patients with Parkinson's disease did not correlate with age (Spearman r = 0.24), disease duration (Spearman r = 0.28), levodopa equivalent unit intake (Spearman r = 0.32), UPDRS motor subscale-3 score in OFF stage (Spearman r = 0.32) or UPDRS-3 score in ON stage (Spearman r = 0.08). Table 4 and (Table 5 and 
Fluorine-18-dopa findings

Clinical correlations
Correlation analyses between clinical characteristics of patients with Parkinson's disease and regional 11 C-DASB BP ND or 18 F-dopa Ki are summarized in Tables 6 and 7 .
Discussion
This study has shown that the presence of fatigue in Parkinson's disease is associated with relative serotonergic denervation in the basal ganglia and associated limbic circuits compared with non-fatigued cases. With a region of interest analytical approach, we found that SERT availability, as reflected by 11 C-DASB binding, was significantly reduced in both dorsal and ventral striatum, and in the thalamus of patients in the Parkinson's disease with fatigue group compared with those in the Parkinson's disease without fatigue group.
Voxel-based analysis comparing the Parkinson's disease without fatigue and Parkinson's disease with fatigue groups confirmed and extended the findings from the region of interest analysis. In the Parkinson's disease with fatigue group, clusters of significant decreases in 11 C-DASB BP ND were localized in the whole striatum, in the thalami and in additional cortical regions, including the cingulate gyrus (Brodmann areas 24 and 32 bilaterally), right paracentral lobule (Brodmann area 31), left insula and right amygdala relative to non-fatigued cases (Fig. 4) left insula in the latter group (Fig. 1) (Schifitto et al., 2008) . Taken together, these findings are against dopaminergic nigrostriatal degeneration per se being a factor in the pathogenesis of fatigue in Parkinson's disease. However, reduced 18 F-dopa uptake in the insular cortex of patients in the
Parkinson's disease with fatigue group suggests a possible link between fatigue and loss of extrastriatal dopaminergic function. The Parkinson's disease without fatigue and Parkinson's disease with fatigue groups were carefully matched for gender, age, disease duration, daily levodopa equivalent units and severity of motor symptoms, as measured by the UPDRS, in both OFF and ON conditions. Patients with Parkinson's disease with dementia, overt depression and excessive daytime sleepiness, a common confounder of fatigue, were not included in the study and so the differential PET findings observed in the Parkinson's disease with fatigue group should be specific for fatigue in Parkinson's disease.
11
C-DASB has high specificity and sensitivity for SERT (nanomolar affinity) and much lower affinity for the dopamine and norepinephrine transporters (micromolar affinity) (Houle et al., 2000) . It is likely that decrease of 11 C-DASB binding reflects Coordinates are MNI space; BA = Brodmann area.
a functional loss of SERT-expressing terminals in the corresponding areas of the brain due to degeneration of the serotonergic pathways. It could be argued that low 11 C-DASB binding simply reflects downregulation of SERT expression. However, several post-mortem studies have now demonstrated depletion of serotonin and SERT levels in the striatum, as well as in extrastriatal areas in patients with Parkinson's disease (Scatton et al., 1983; Shannak et al., 1994; Kish et al., 2008) . In particular, Kish et al. (2008) reported that SERT and other serotonergic markers, including serotonin itself, were significantly reduced in the striatum of patients with Parkinson's disease compared with controls. There was a preferential loss of SERT and serotonin in the caudate compared with the putamen. These workers also found that changes in striatal SERT binding in Parkinson's disease brains reflected an actual reduction in levels of SERT protein.
The basal ganglia receive sensory and motor input from all cortical areas and are a relay in neuronal pathways processing emotional, motivational, associative and cognitive functions. A major role of the basal ganglia is to integrate sensorimotor, associative, limbic and motor information into efficient thought and action (Bolam et al., 2000) . It has been suggested that structural lesions and/or changes in the neurotransmitter balance within the basal ganglia and associated structures disrupt the process of integration of limbic input concerning emotional status and consequent motor output. Dissociation of motivation from executive motor movement could lead to a reluctance to act and a feeling of fatigue (Chaudhuri et al., 2000) . In line with this, Hagell and Brundin (2009) reported that lack of motivation is a significant predictor of fatigue in patients with Parkinson's disease. Our findings provide strong evidence in support of this pathophysiological model of fatigue in Parkinson's disease. Patients in the Parkinson's disease with fatigue group showed reduced SERT expression in the main components of the basal ganglia, including the ventral striatum where the limbic-to-motor integration takes place (Mogenson et al., 1980) .
Decreases of 11 C-DASB binding in the Parkinson's disease with fatigue group were also found in limbic structures including: (i) Brodmann areas 24 and 31, corresponding to the ventral portion and the isthmus of the cingulate gyrus, respectively, both involved in emotion processing; (ii) Brodmann area 32, corresponding to the dorsal anterior cingulate cortex anterior, which is involved in decision making processes and (iii) the amygdala, which is involved in the processing of emotional reactions and emotional memory as well as spatial and motor learning. The insular cortex is also a component of the limbic system. It has reciprocal connections with the anterior cingulate, amygdala, basal ganglia and prefrontal cortex and could represent a centre of multi-modal sensory-motor-limbic integration (Agustine, 1996) . It is known to play a role in regulating autonomic functions. Changes in 11 C-DASB binding and 18 F-dopa uptake were observed in the left insular cortex of patients in the Parkinson's disease with fatigue group. An asymmetrical involvement of the insular cortex is a little unexpected and this apparent lateralization of PET findings could reflect lack of power due to the relatively small number of patients in this study.
To date, the dopamine transporter blocker, methylphenidate, at a dose of 10 mg three times a day, is the only drug that has shown significant improvement of fatigue in patients with Parkinson's disease in controlled studies (Mendonca et al., 2007) , whereas open label studies have indicated a beneficial effect of some dopaminergic agents such as levodopa and apomorphine infusion (Honig et al., 2009; Naidu et al., 2009) . Selective serotonin reuptake inhibitors are commonly used in the treatment of chronic fatigue syndrome and are often used in patients with Parkinson's disease with history of fatigue. These medications increase synaptic levels of serotonin by inhibiting SERT activity. However, if our finding of low 11 C-DASB binding reflects an effective loss of SERT protein, as observed in post-mortem parkinsonian brain, selective serotonin reuptake inhibitors are less likely to be efficacious in these patients. Alternative strategies to increase brain level of serotonin and serotonergic transmission in non-depressed patients with Parkinson's disease with fatigue should be tested. Fatigue is a common symptom in other diseases including chronic fatigue syndrome, multiple sclerosis and stroke. It is possible that a dysfunction of brain serotonergic pathways in the basal ganglia/limbic systems may be common to the occurrence of fatigue in these conditions. Preliminary reports of a serotonergic dysfunction in patients with chronic fatigue syndrome without Parkinson's disease support this hypothesis. Using the PET ligand 11 C-(+)McN5652, Yamamoto et al. (2004) marked in the hippocampus bilaterally. Other limbic areas, including the amygdala, insular and anterior cingulate, also showed significant tracer binding reduction in the chronic fatigue syndrome group. Although serotonergic function has not been investigated in vivo in patients with multiple sclerosis with fatigue, an early PET study (Roelcke et al., 1997) demonstrated that these patients had reduced glucose metabolism in the basal ganglia and in the lateral and medial prefrontal cortices, the same areas where serotonergic dysfunction was seen in our patients with Parkinson's disease with fatigue. Future research is required to clarify the role of serotonergic dysfunction in the pathogenesis of fatigue in these clinical conditions. There are a few more findings of this study that need further consideration. In line with other PET studies suggesting raphe involvement in advanced Parkinson's disease (Rakshi et al., 1999; Moore et al., 2008), 11 C-DASB BP ND values in the raphe inversely correlated with disease duration in the cohort of patients with Parkinson's disease. Yet, raphe median 11 C-DASB BP ND values in the Parkinson's disease without fatigue and Parkinson's disease with fatigue groups were similar and were not significantly different from the control subjects. Since the majority of the serotonin innervation of the brain arises from the raphe nuclei (Hornung, 2003) , one might have expected more severe raphe involvement in the Parkinson's disease with fatigue group to parallel the striatal/cortical changes. However, our findings are in agreement with earlier reports. Albin et al. (2008) , who used 11 C-DASB PET to assess brain serotonergic pathway function in patients with early Parkinson's disease, also found that the magnitude of SERT binding reductions in patients with Parkinson's disease compared with controls was greater in the forebrain than in brainstem regions. Additionally, receptor autoradiography with 3 H-citalopram, a marker of SERT, showed a normal density of 3 H-citalopram binding sites in the median raphe of patients with Parkinson's disease, despite severe binding reductions in both the basal ganglia and cerebral cortex (Chinaglia et al., 1993) . A possible explanation for these findings is that the degenerative process in the raphe-striatal neurons in Parkinson's disease targets the nerve terminals rather than the cell bodies. Although the Parkinson's disease without fatigue and Parkinson's disease with fatigue groups were age-matched, our healthy control subjects used for the 11 C-DASB PET comparisons were 20 years younger than the patients with Parkinson's disease. An age-related decline in the availability of SERT when measured with PET and single photon emission computed tomography has been reported. Buchert et al. (2006) reviewed this topic. The percentage reduction in SERT availability per decade across published series varies from 2 to 10.5% (median 50th percentile 4.5%). Based on these observations, the maximum decline in 11 C-DASB binding in our two
Parkinson's disease cohorts that could be ascribed to ageing is $21%. This is far less than the decline observed in this study, as the Parkinson's disease with fatigue group had a reduction close to 80% of the control mean in most of the regions assessed by the region of interest approach (Table 4) . Therefore, the reduction in 11 C-DASB binding observed in the Parkinson's disease with fatigue group is unlikely to be explained by ageing alone. Although findings from this study indicate that the level of dopaminergic nigrostriatal dysfunction does not differentiate patients with Parkinson's disease with and without fatigue, they do not exclude loss of striatal dopamine playing a role in its pathogenesis. Although fatigue is associated with more severe involvement of the serotonergic system in patients with Parkinson's disease, it is likely that changes in the serotonin/dopamine balance within the basal ganglia also contribute.
Finally, by excluding patients with dementia, depression and excessive daytime sleepiness, we have reduced the effects of possible confounding factors and shed light on the pathogenesis of 'primary' fatigue in Parkinson's disease. However, all these other factors are known to exacerbate the subjective experience of fatigue and in some cases could be the predominant cause for fatigue-like symptoms. Distinct neurochemical substrates could underlie these situations and need to be investigated carefully so that focused interventions can optimize the treatment of fatigue in patients with Parkinson's disease.
